JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2003; 42:1900-1905, doi:10.1016/j.jacc.2003.06.012
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iakovou, I.
Right arrow Articles by Leon, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iakovou, I.
Right arrow Articles by Leon, M. B.

Increased CK-MB release is a "trade-off" for optimal stent implantation

an intravascular ultrasound study

Ioannis Iakovou, MD*, Gary S. Mintz, MD*, George Dangas, MD, PhD*,*, Alexandre Abizaid, MD*, Roxana Mehran, MD*, Yoshio Kobayashi, MD*, Alexandra J. Lansky, MD*, Eve D. Aymong, MD, MSc*, Eugenia Nikolsky, MD*, Gregg W. Stone, MD*, Jeffrey W. Moses, MD* and Martin B. Leon, MD*

* Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York, USA



View larger version (29K):

[in a new window]
  		Figure 1 Creatine kinase-MB isoenzyme elevation (CK-MB) post percutaneous coronary intervention according to stent expansion. CK-MB release one to three times normal was similar in Group 1 (stent expansion <70%) vs. Group 2 (stent expansion 70% to 100%) vs. Group 3 (stent expansion >100%). However, there was a stepwise increase in CK-MB 3 to 5 times and >5 times normal in Group 1 vs. Group 2 vs. Group 3.

 


View larger version (22K):

[in a new window]
  		Figure 2 One-year cumulative outcome. There was a stepwise decrease in death, multiple adverse cardiac events, and target lesion revascularization in Group 1 (stent expansion <70%) vs. Group 2 (stent expansion 70% to 100%) vs. Group 3 (stent expansion >100%). MACE = multiple adverse cardiac events; Q-W MI = Q-wave myocardial infarction; TLR = target lesion revascularization.

 


View larger version (19K):

[in a new window]
  		Figure 3 The occurrence of any target lesion revascularization event decreased with increasing percent stent expansion (% stent expansion = final stent CSA/[proximal CSA + distal CSA]/2). CSA = cross-sectional area.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.